{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T10:29:56Z","timestamp":1789036196422,"version":"build-2803163510"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T00:00:00Z","timestamp":1601337600000},"content-version":"vor","delay-in-days":272,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015993","name":"Kowa Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015993","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jvsvs.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JVS-Vascular Science"],"published-print":{"date-parts":[[2020]]},"DOI":"10.1016\/j.jvssci.2020.09.005","type":"journal-article","created":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T11:33:43Z","timestamp":1603452823000},"page":"219-232","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["K-134, a phosphodiesterase 3 inhibitor, reduces vascular inflammation and hypoxia, and prevents rupture of experimental abdominal aortic aneurysms"],"prefix":"10.1016","volume":"1","author":[{"given":"Naoki","family":"Unno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuro","family":"Yata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Kayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Yamanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Tsuyuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Sano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunori","family":"Inuzuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ena","family":"Naruse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroya","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jvssci.2020.09.005_bib1","doi-asserted-by":"crossref","first-page":"e81260","DOI":"10.1371\/journal.pone.0081260","article-title":"Prevalence and trends of the abdominal aortic aneurysms epidemic in general population--a meta-analysis","volume":"8","author":"Li","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jvssci.2020.09.005_bib2","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.2174\/1389450119666171227223331","article-title":"Current status and perspectives on pharmacologic therapy for abdominal aortic aneurysm","volume":"19","author":"Yoshimura","year":"2018","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.jvssci.2020.09.005_bib3","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1586\/14779072.2015.1074861","article-title":"Understanding the pathogenesis of abdominal aortic aneurysms","volume":"13","author":"Kuivaniemi","year":"2015","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.jvssci.2020.09.005_bib4","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1016\/j.jvs.2011.12.075","article-title":"Calcium channel blockers enhance sac shrinkage after endovascular aneurysm repair","volume":"55","author":"Bailey","year":"2012","journal-title":"J\u00a0Vasc Surg"},{"key":"10.1016\/j.jvssci.2020.09.005_bib5","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1067\/mva.2002.121308","article-title":"Propranolol for small abdominal aortic aneurysms: results of a randomized trial","volume":"35","year":"2002","journal-title":"J\u00a0Vasc Surg"},{"key":"10.1016\/j.jvssci.2020.09.005_bib6","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1093\/eurheartj\/ehw257","article-title":"An evaluation of the effect of an angiotensin-converting enzyme inhibitor on the growth rate of small abdominal aortic aneurysms: a randomized placebo-controlled trial (AARDVARK)","volume":"37","author":"Bicknell","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jvssci.2020.09.005_bib7","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.2174\/1389450119666171227224655","article-title":"Fenofibrate and telmisartan in the management of abdominal aortic aneurysm","volume":"19","author":"Rowbotham","year":"2018","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.jvssci.2020.09.005_bib8","doi-asserted-by":"crossref","first-page":"815","DOI":"10.7326\/0003-4819-159-12-201312170-00007","article-title":"Doxycycline for stabilization of abdominal aortic aneurysms","volume":"159","author":"Meijer","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jvssci.2020.09.005_bib9","first-page":"450","article-title":"The effect of ticagrelor on growth of small abdominal aortic aneurysms - a randomized controlled trial","volume":"116","author":"Wanhainen","year":"2020","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jvssci.2020.09.005_bib10","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1097\/HCO.0000000000000216","article-title":"Abdominal aortic aneurysm: novel mechanisms and therapies","volume":"30","author":"Davis","year":"2015","journal-title":"Curr Opin Cardiol"},{"key":"10.1016\/j.jvssci.2020.09.005_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13063-016-1752-z","article-title":"Fenofibrate in the management of AbdoMinal aortic anEurysm (FAME): study protocol for a randomised controlled trial","volume":"18","author":"Rowbotham","year":"2017","journal-title":"Trials"},{"key":"10.1016\/j.jvssci.2020.09.005_bib12","doi-asserted-by":"crossref","first-page":"e009866","DOI":"10.1161\/JAHA.118.009866","article-title":"Randomized placebo-controlled trial assessing the effect of 24-week fenofibrate therapy on circulating markers of abdominal aortic aneurysm: outcomes from the FAME -2 trial","volume":"7","author":"Pinchbeck","year":"2018","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jvssci.2020.09.005_bib13","doi-asserted-by":"crossref","first-page":"4000","DOI":"10.2174\/1381612821666150826095346","article-title":"Emerging pharmacological treatments to prevent abdominal aortic aneurysm growth and rupture","volume":"21","author":"Fraga-Silva","year":"2015","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.jvssci.2020.09.005_bib14","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1002\/bjs.9824","article-title":"Randomized clinical trial of mast cell inhibition in patients with a medium-sized abdominal aortic aneurysm","volume":"102","author":"Sillesen","year":"2015","journal-title":"Br J Surg"},{"key":"10.1016\/j.jvssci.2020.09.005_bib15","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jvs.2016.08.003","article-title":"Challenges and opportunities in limiting abdominal aortic aneurysm growth","volume":"65","author":"Golledge","year":"2017","journal-title":"J\u00a0Vasc Surg"},{"key":"10.1016\/j.jvssci.2020.09.005_bib16","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1161\/CIRCRESAHA.118.312439","article-title":"Pharmacologic management of aneurysms","volume":"124","author":"Lindeman","year":"2019","journal-title":"Circ Res"},{"key":"10.1016\/j.jvssci.2020.09.005_bib17","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S0006-2952(99)00346-9","article-title":"Potent effects of novel anti-platelet aggregatory cilostamide analogues on recombinant cyclic nucleotide phosphodiesterase isozyme activity","volume":"59","author":"Sudo","year":"2000","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.jvssci.2020.09.005_bib18","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1160\/TH10-07-0439","article-title":"Shear-dependent suppression of platelet thrombus formation by phosphodiesterase 3 inhibition requires low levels of concomitant Gs-coupled receptor stimulation","volume":"105","author":"Yoshida","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jvssci.2020.09.005_bib19","doi-asserted-by":"crossref","first-page":"e385","DOI":"10.1016\/j.jss.2011.01.017","article-title":"Suppression of experimental abdominal aortic aneurysm in a rat model by the phosphodiesterase 3 inhibitor cilostazol","volume":"167","author":"Zhang","year":"2011","journal-title":"J\u00a0Surg Res"},{"key":"10.1016\/j.jvssci.2020.09.005_bib20","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1161\/ATVBAHA.117.309707","article-title":"Cilostazol attenuates angiotensin II-induced abdominal aortic aneurysms but not atherosclerosis in apolipoprotein E-deficient mice","volume":"38","author":"Umebayashi","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jvssci.2020.09.005_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.jvs.2011.09.004","article-title":"A\u00a0phase II dose-ranging study of the phosphodiesterase inhibitor K-134 in patients with peripheral artery disease and claudication","volume":"55","author":"Brass","year":"2012","journal-title":"J\u00a0Vasc Surg"},{"key":"10.1016\/j.jvssci.2020.09.005_bib22","doi-asserted-by":"crossref","first-page":"e46432","DOI":"10.1371\/journal.pone.0046432","article-title":"K-134, a phosphodiesterase 3 inhibitor, prevents brain damage by inhibiting thrombus formation in a rat cerebral infarction model","volume":"7","author":"Yoshida","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jvssci.2020.09.005_bib23","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejphar.2012.05.014","article-title":"K-134, a phosphodiesterase 3 inhibitor, improves gait disturbance and hindlimb blood flow impairment in rat peripheral artery disease models","volume":"689","author":"Sasaki","year":"2012","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jvssci.2020.09.005_bib24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0134386","article-title":"Hypoperfusion of the adventitial vasa vasorum develops an abdominal aortic aneurysm","volume":"10","author":"Tanaka","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jvssci.2020.09.005_bib25","first-page":"55763","article-title":"Creation of a rodent model of abdominal aortic aneurysm by blocking adventitial vasa vasorum perfusion","volume":"129","author":"Tanaka","year":"2017","journal-title":"J\u00a0Vis Exp"},{"key":"10.1016\/j.jvssci.2020.09.005_bib26","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1172\/JCI7818","article-title":"Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice","volume":"105","author":"Daugherty","year":"2000","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jvssci.2020.09.005_bib27","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1161\/ATVBAHA.119.312659","article-title":"SGLT-2 (Sodium-Glucose Cotransporter 2) inhibition reduces Ang II (Angiotensin II)-induced dissecting abdominal aortic aneurysm in ApoE (Apolipoprotein E) knockout mice","volume":"39","author":"Ortega","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jvssci.2020.09.005_bib28","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.jvs.2010.05.089","article-title":"Vascular smooth muscle cell peroxisome proliferator-activated receptor-gamma deletion promotes abdominal aortic aneurysms","volume":"52","author":"Hamblin","year":"2010","journal-title":"J\u00a0Vasc Surg"},{"key":"10.1016\/j.jvssci.2020.09.005_bib29","doi-asserted-by":"crossref","first-page":"e57398","DOI":"10.1371\/journal.pone.0057398","article-title":"Adventitial vasa vasorum arteriosclerosis in abdominal aortic aneurysm","volume":"8","author":"Tanaka","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jvssci.2020.09.005_bib30","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1345\/aph.19408","article-title":"Cilostazol: treatment of intermittent claudication","volume":"35","author":"Reilly","year":"2001","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jvssci.2020.09.005_bib31","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/j.1476-5381.2011.01540.x","article-title":"Intermedin (adrenomedullin2) stabilizes the endothelial barrier and antagonizes thrombin-induced barrier failure in endothelial cell monolayers","volume":"165","author":"Aslam","year":"2012","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jvssci.2020.09.005_bib32","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.atherosclerosis.2017.10.011","article-title":"Intermedin reduces neointima formation by regulating vascular smooth muscle cell phenotype via cAMP\/PKA pathway","volume":"266","author":"Zhu","year":"2017","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jvssci.2020.09.005_bib33","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/00005344-199212000-00009","article-title":"Effect of cilostazol, a cyclic AMP phosphodiesterase inhibitor, on the proliferation of rat aortic smooth muscle cells in culture","volume":"20","author":"Takahashi","year":"1992","journal-title":"J\u00a0Cardiovasc Pharmacol"},{"key":"10.1016\/j.jvssci.2020.09.005_bib34","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1161\/ATVBAHA.116.307825","article-title":"Intermedin1-53 attenuates abdominal aortic aneurysm by inhibiting oxidative stress","volume":"36","author":"Lu","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jvssci.2020.09.005_bib35","first-page":"A14430","article-title":"The novel phosphodiesterase 3 inhibitor K-134 improves walking performance in Japanese patients with intermittent claudication","volume":"124","author":"Shigematsu","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.jvssci.2020.09.005_bib36","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S0741-5214(03)00791-2","article-title":"Influence of intraluminal thrombus on structural and cellular composition of abdominal aortic aneurysm wall","volume":"38","author":"Kazi","year":"2003","journal-title":"J\u00a0Vasc Surg"},{"key":"10.1016\/j.jvssci.2020.09.005_bib37","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jvs.2010.08.013","article-title":"Thrombus volume is associated with cardiovascular events and aneurysm growth in patients who have abdominal aortic aneurysms","volume":"53","author":"Parr","year":"2011","journal-title":"J\u00a0Vasc Surg"},{"key":"10.1016\/j.jvssci.2020.09.005_bib38","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1093\/cvr\/cvq337","article-title":"Novel aspects of the pathogenesis of aneurysms of the abdominal aorta in humans","volume":"90","author":"Michel","year":"2011","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jvssci.2020.09.005_bib39","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1161\/CIRCRESAHA.116.306853","article-title":"Cross talk pathways between coagulation and inflammation","volume":"118","author":"Foley","year":"2016","journal-title":"Circ Res"},{"key":"10.1016\/j.jvssci.2020.09.005_bib40","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1067\/mva.2001.114813","article-title":"Association of intraluminal thrombus in abdominal aortic aneurysm with local hypoxia and wall weakening","volume":"34","author":"Vorp","year":"2001","journal-title":"J\u00a0Vasc Surg"},{"key":"10.1016\/j.jvssci.2020.09.005_bib41","doi-asserted-by":"crossref","first-page":"e51707","DOI":"10.1371\/journal.pone.0051707","article-title":"Clopidogrel, a platelet P2Y12 receptor inhibitor, reduces vascular inflammation and angiotensin II induced-abdominal aortic aneurysm progression","volume":"7","author":"Liu","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jvssci.2020.09.005_bib42","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1161\/ATVBAHA.115.305537","article-title":"Platelet inhibitors reduce rupture in a mouse model of established abdominal aortic aneurysm","volume":"35","author":"Owens","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jvssci.2020.09.005_bib43","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0021-9150(98)00203-2","article-title":"Milrinone, a phosphodiesterase inhibitor, suppresses intimal thickening after photochemically induced endothelial injury in the mouse femoral artery","volume":"142","author":"Kondo","year":"1999","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jvssci.2020.09.005_bib44","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.2174\/1389450119666180122154409","article-title":"Hypoperfusion of the aortic wall secondary to degeneration of adventitial vasa vasorum causes abdominal aortic aneurysms","volume":"19","author":"Tanaka","year":"2018","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.jvssci.2020.09.005_bib45","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1161\/01.ATV.19.4.870","article-title":"Evidence of hypoxic areas within the arterial wall in\u00a0vivo","volume":"19","author":"Bjornheden","year":"1999","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jvssci.2020.09.005_bib46","doi-asserted-by":"crossref","first-page":"11574","DOI":"10.3390\/ijms160511574","article-title":"Vasa vasorum in atherosclerosis and clinical significance","volume":"16","author":"Xu","year":"2015","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jvssci.2020.09.005_bib47","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jvs.2010.05.090","article-title":"Analysis of risk factors for abdominal aortic aneurysm in a cohort of more than 3 million individuals","volume":"52","author":"Kent","year":"2010","journal-title":"J\u00a0Vasc Surg"},{"key":"10.1016\/j.jvssci.2020.09.005_bib48","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.atherosclerosis.2016.02.007","article-title":"Topologic distributions of vasa vasorum and lymphatic vasa vasorum in the aortic adventitia-implications for the prevalence of aortic diseases","volume":"247","author":"Sano","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jvssci.2020.09.005_bib49","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1093\/cvr\/cvt146","article-title":"Role of macrophage-derived hypoxia-inducible factor (HIF)-1alpha as a mediator of vascular remodelling","volume":"99","author":"Nakayama","year":"2013","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jvssci.2020.09.005_bib50","doi-asserted-by":"crossref","first-page":"H1168","DOI":"10.1152\/ajpheart.00296.2017","article-title":"Role of myeloperoxidase in abdominal aortic aneurysm formation: mitigation by taurine","volume":"313","author":"Kim","year":"2017","journal-title":"Am J Physiol Heart Circ Physiol"}],"container-title":["JVS-Vascular Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666350320300262?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666350320300262?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T21:14:11Z","timestamp":1762982051000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666350320300262"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":50,"alternative-id":["S2666350320300262"],"URL":"https:\/\/doi.org\/10.1016\/j.jvssci.2020.09.005","relation":{},"ISSN":["2666-3503"],"issn-type":[{"value":"2666-3503","type":"print"}],"subject":[],"published":{"date-parts":[[2020]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"K-134, a phosphodiesterase 3 inhibitor, reduces vascular inflammation and hypoxia, and prevents rupture of experimental abdominal aortic aneurysms","name":"articletitle","label":"Article Title"},{"value":"JVS-Vascular Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jvssci.2020.09.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by the Society for Vascular Surgery. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}